The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates
Identifieur interne : 000F46 ( Main/Exploration ); précédent : 000F45; suivant : 000F47The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates
Auteurs : M. Lagière [France] ; S. Navailles [France] ; L. Mignon [États-Unis] ; A. Roumegous [France] ; M.-F. Chesselet [États-Unis] ; P. De Deurwaerdère [France]Source :
- Experimental brain research [ 0014-4819 ] ; 2013.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Administration, Oral, Agonist, Animal, Animals, Basal Ganglia (drug effects), Basal Ganglia (metabolism), Basal ganglion, Corpus Striatum (drug effects), Corpus Striatum (metabolism), Disease Models, Animal, Electrophysiological Phenomena (physiology), Electrophysiology, Entopeduncular Nucleus (drug effects), Entopeduncular Nucleus (metabolism), Ethylamines (administration & dosage), Ethylamines (pharmacology), Globus Pallidus (drug effects), Globus Pallidus (metabolism), Indoles (administration & dosage), Indoles (pharmacology), Male, Neurons (drug effects), Oxidopamine, Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson disease, Rat, Rats, Rats, Sprague-Dawley, Serotonin, Serotonin (metabolism), Serotonin 5-HT2 Receptor Agonists (administration & dosage), Serotonin 5-HT2 Receptor Agonists (pharmacology), Substantia Nigra (drug effects), Substantia Nigra (metabolism).
- MESH :
- chemical , administration & dosage : Ethylamines, Indoles, Serotonin 5-HT2 Receptor Agonists.
- drug effects : Basal Ganglia, Corpus Striatum, Entopeduncular Nucleus, Globus Pallidus, Neurons, Substantia Nigra.
- drug therapy : Parkinson Disease.
- metabolism : Basal Ganglia, Corpus Striatum, Entopeduncular Nucleus, Globus Pallidus, Parkinson Disease, Serotonin, Substantia Nigra.
- chemical , pharmacology : Ethylamines, Indoles, Serotonin 5-HT2 Receptor Agonists.
- physiology : Electrophysiological Phenomena.
- Administration, Oral, Animals, Disease Models, Animal, Male, Rats, Rats, Sprague-Dawley.
Abstract
Lesions of nigrostriatal dopaminergic neurons as seen in Parkinson's disease (PD) increase orofacial responses to serotonergic (5-HT) agonists in rodents. Although this response to 5-HT agonists has been related to aberrant signalling in the basal ganglia, a group a subcortical structures involved in the control of motor behaviours, it deserves additional studies with respect to the specific loci involved. Using measurements of orofacial activity, as well as single-cell recordings in vivo, we have studied the role of the entopeduncular nucleus (EPN; equivalent to the internal globus pallidus of primates), an output structure of basal ganglia, in the hypersensitized responses to a 5-HT agonist in sham- or unilaterally dopamine-depleted rats. Intra-EPN injections of Ro 60-0175 (0.3 and 1 μg/100 nl) promoted robust oral movements in 6-OHDA rats without affecting oral activity in sham-depleted rats. Peripheral administration of Ro 60-0175 (3 mg/kg ip) decreased EPN neuronal firing rate in 6-OHDA rats compared to sham-depleted rats. Such an effect was also observed when the agonist (0.2 μg/20 nl) was locally applied onto EPN neurons. These data demonstrate the contribution of EPN to hypersensitized responses to 5-HT agonists in a rat model of PD.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000083
- to stream PascalFrancis, to step Curation: 001210
- to stream PascalFrancis, to step Checkpoint: 000076
- to stream Main, to step Merge: 000F74
- to stream PubMed, to step Corpus: 000679
- to stream PubMed, to step Curation: 000651
- to stream PubMed, to step Checkpoint: 000651
- to stream Ncbi, to step Merge: 001111
- to stream Ncbi, to step Curation: 001111
- to stream Ncbi, to step Checkpoint: 001111
- to stream Hal, to step Corpus: 000B28
- to stream Hal, to step Curation: 000B28
- to stream Hal, to step Checkpoint: 000398
- to stream Main, to step Merge: 000C31
- to stream Main, to step Curation: 000F46
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The enhanced oral response to the 5-HT<sub>2</sub> agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates</title><author><name sortKey="Lagiere, M" sort="Lagiere, M" uniqKey="Lagiere M" first="M." last="Lagière">M. Lagière</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifiqlle, Université Bordeaux, 146, rue Léo Saignat</s1><s2>33076 Bordeaux</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Navailles, S" sort="Navailles, S" uniqKey="Navailles S" first="S." last="Navailles">S. Navailles</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifiqlle, Université Bordeaux, 146, rue Léo Saignat</s1><s2>33076 Bordeaux</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Mignon, L" sort="Mignon, L" uniqKey="Mignon L" first="L." last="Mignon">L. Mignon</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Neurology, David Geffen School of Medicine, UCLA</s1><s2>Los Angeles, CA 90095-1769</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Roumegous, A" sort="Roumegous, A" uniqKey="Roumegous A" first="A." last="Roumegous">A. Roumegous</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifiqlle, Université Bordeaux, 146, rue Léo Saignat</s1><s2>33076 Bordeaux</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Chesselet, M F" sort="Chesselet, M F" uniqKey="Chesselet M" first="M.-F." last="Chesselet">M.-F. Chesselet</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Neurology, David Geffen School of Medicine, UCLA</s1><s2>Los Angeles, CA 90095-1769</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P." last="De Deurwaerdère">P. De Deurwaerdère</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifiqlle, Université Bordeaux, 146, rue Léo Saignat</s1><s2>33076 Bordeaux</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">13-0340362</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 13-0340362 INIST</idno><idno type="RBID">Pascal:13-0340362</idno><idno type="wicri:Area/PascalFrancis/Corpus">000083</idno><idno type="wicri:Area/PascalFrancis/Curation">001210</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000076</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000076</idno><idno type="wicri:doubleKey">0014-4819:2013:Lagiere M:the:enhanced:oral</idno><idno type="wicri:Area/Main/Merge">000F74</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:23535834</idno><idno type="wicri:Area/PubMed/Corpus">000679</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000679</idno><idno type="wicri:Area/PubMed/Curation">000651</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000651</idno><idno type="wicri:Area/PubMed/Checkpoint">000651</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000651</idno><idno type="wicri:Area/Ncbi/Merge">001111</idno><idno type="wicri:Area/Ncbi/Curation">001111</idno><idno type="wicri:Area/Ncbi/Checkpoint">001111</idno><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:hal-01377276</idno><idno type="url">https://hal.archives-ouvertes.fr/hal-01377276</idno><idno type="wicri:Area/Hal/Corpus">000B28</idno><idno type="wicri:Area/Hal/Curation">000B28</idno><idno type="wicri:Area/Hal/Checkpoint">000398</idno><idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000398</idno><idno type="wicri:doubleKey">0014-4819:2013:Lagiere M:the:enhanced:oral</idno><idno type="wicri:Area/Main/Merge">000C31</idno><idno type="wicri:Area/Main/Curation">000F46</idno><idno type="wicri:Area/Main/Exploration">000F46</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The enhanced oral response to the 5-HT<sub>2</sub> agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates</title><author><name sortKey="Lagiere, M" sort="Lagiere, M" uniqKey="Lagiere M" first="M." last="Lagière">M. Lagière</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifiqlle, Université Bordeaux, 146, rue Léo Saignat</s1><s2>33076 Bordeaux</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Navailles, S" sort="Navailles, S" uniqKey="Navailles S" first="S." last="Navailles">S. Navailles</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifiqlle, Université Bordeaux, 146, rue Léo Saignat</s1><s2>33076 Bordeaux</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Mignon, L" sort="Mignon, L" uniqKey="Mignon L" first="L." last="Mignon">L. Mignon</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Neurology, David Geffen School of Medicine, UCLA</s1><s2>Los Angeles, CA 90095-1769</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Roumegous, A" sort="Roumegous, A" uniqKey="Roumegous A" first="A." last="Roumegous">A. Roumegous</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifiqlle, Université Bordeaux, 146, rue Léo Saignat</s1><s2>33076 Bordeaux</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Chesselet, M F" sort="Chesselet, M F" uniqKey="Chesselet M" first="M.-F." last="Chesselet">M.-F. Chesselet</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Neurology, David Geffen School of Medicine, UCLA</s1><s2>Los Angeles, CA 90095-1769</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P." last="De Deurwaerdère">P. De Deurwaerdère</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifiqlle, Université Bordeaux, 146, rue Léo Saignat</s1><s2>33076 Bordeaux</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Experimental brain research</title><title level="j" type="abbreviated">Exp. brain res.</title><idno type="ISSN">0014-4819</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Experimental brain research</title><title level="j" type="abbreviated">Exp. brain res.</title><idno type="ISSN">0014-4819</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Agonist</term><term>Animal</term><term>Animals</term><term>Basal Ganglia (drug effects)</term><term>Basal Ganglia (metabolism)</term><term>Basal ganglion</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (metabolism)</term><term>Disease Models, Animal</term><term>Electrophysiological Phenomena (physiology)</term><term>Electrophysiology</term><term>Entopeduncular Nucleus (drug effects)</term><term>Entopeduncular Nucleus (metabolism)</term><term>Ethylamines (administration & dosage)</term><term>Ethylamines (pharmacology)</term><term>Globus Pallidus (drug effects)</term><term>Globus Pallidus (metabolism)</term><term>Indoles (administration & dosage)</term><term>Indoles (pharmacology)</term><term>Male</term><term>Neurons (drug effects)</term><term>Oxidopamine</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson disease</term><term>Rat</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Serotonin</term><term>Serotonin (metabolism)</term><term>Serotonin 5-HT2 Receptor Agonists (administration & dosage)</term><term>Serotonin 5-HT2 Receptor Agonists (pharmacology)</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Ethylamines</term><term>Indoles</term><term>Serotonin 5-HT2 Receptor Agonists</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term><term>Corpus Striatum</term><term>Entopeduncular Nucleus</term><term>Globus Pallidus</term><term>Neurons</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia</term><term>Corpus Striatum</term><term>Entopeduncular Nucleus</term><term>Globus Pallidus</term><term>Parkinson Disease</term><term>Serotonin</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Ethylamines</term><term>Indoles</term><term>Serotonin 5-HT2 Receptor Agonists</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Electrophysiological Phenomena</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Disease Models, Animal</term><term>Male</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term><term>Electrophysiologie</term><term>Sérotonine</term><term>Noyau gris central</term><term>Oxidopamine</term><term>Maladie de Parkinson</term><term>Rat</term><term>Animal</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lesions of nigrostriatal dopaminergic neurons as seen in Parkinson's disease (PD) increase orofacial responses to serotonergic (5-HT) agonists in rodents. Although this response to 5-HT agonists has been related to aberrant signalling in the basal ganglia, a group a subcortical structures involved in the control of motor behaviours, it deserves additional studies with respect to the specific loci involved. Using measurements of orofacial activity, as well as single-cell recordings in vivo, we have studied the role of the entopeduncular nucleus (EPN; equivalent to the internal globus pallidus of primates), an output structure of basal ganglia, in the hypersensitized responses to a 5-HT agonist in sham- or unilaterally dopamine-depleted rats. Intra-EPN injections of Ro 60-0175 (0.3 and 1 μg/100 nl) promoted robust oral movements in 6-OHDA rats without affecting oral activity in sham-depleted rats. Peripheral administration of Ro 60-0175 (3 mg/kg ip) decreased EPN neuronal firing rate in 6-OHDA rats compared to sham-depleted rats. Such an effect was also observed when the agonist (0.2 μg/20 nl) was locally applied onto EPN neurons. These data demonstrate the contribution of EPN to hypersensitized responses to 5-HT agonists in a rat model of PD.</div></front></TEI><affiliations><list><country><li>France</li><li>États-Unis</li></country><region><li>Aquitaine</li><li>Californie</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Bordeaux</li></settlement></list><tree><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Lagiere, M" sort="Lagiere, M" uniqKey="Lagiere M" first="M." last="Lagière">M. Lagière</name></region><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P." last="De Deurwaerdère">P. De Deurwaerdère</name><name sortKey="Navailles, S" sort="Navailles, S" uniqKey="Navailles S" first="S." last="Navailles">S. Navailles</name><name sortKey="Roumegous, A" sort="Roumegous, A" uniqKey="Roumegous A" first="A." last="Roumegous">A. Roumegous</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Mignon, L" sort="Mignon, L" uniqKey="Mignon L" first="L." last="Mignon">L. Mignon</name></region><name sortKey="Chesselet, M F" sort="Chesselet, M F" uniqKey="Chesselet M" first="M.-F." last="Chesselet">M.-F. Chesselet</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F46 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F46 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:13-0340362
|texte= The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates
}}
| This area was generated with Dilib version V0.6.29. |  |